Skip to content
value.today

Elevation Pharmaceuticals Inc.

🇺🇸 San Diego, California, USABiotechnologyFounded 2007
Total raised
$27 M
2 rounds on record
Latest round
$12 M
Dec 2011
First round on record
Jan 2010
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Elevation Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2011$12 MNo. 2$10 to $50 million

Elevation Pharmaceuticals Inc.: Raise no. 2, Dec 2011

Investors in this round

6 investors had bought by the notice of Dec 20, 2011: 6 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$12 M of $30 M offered; $18 M still to sell
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Ahmet K. Tutuncu, M.D., Ph.D. · Executive Officer
  • Cam L. Garner · Executive Officer, Director
  • Jaisim K. Shah · Executive Officer
  • Pravin K. Soni, Ph.D. · Executive Officer
  • William M. Gerhart · Executive Officer, Director
  • Brenton K. Ahrens · Director
  • Heath K. Lukatch · Director
  • Heather K. Preston, M.D. · Director
  • Jan K. Leschly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William M. Gerhart, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 20, 2011. Read the notice at the SEC.

equitySEC
Jan 2010$15 MNo. 1$10 to $50 million

Elevation Pharmaceuticals Inc.: Raise no. 1, Jan 2010

Investors in this round

28 investors had bought by the notice of Jan 26, 2010: 28 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$15 M of $32 M offered; $17 M still to sell
Smallest investment taken
$1
What was sold
equity
Exemption claimed
  • 06
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions and finders' fees and payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Cam L. Garner · Executive Officer, Director
  • William M. Gerhart · Executive Officer, Director
  • Brenton K. Ahrens · Director
  • Heather K. Preston, M.D. · Director
  • Jan K. Leschly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by William M. Gerhart, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 26, 2010. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Elevation Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2011).

    SEC Form D · Dec 2011

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Dec 2011

That is all the official record says: Elevation Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Elevation Pharmaceuticals Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 28 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Elevation Pharmaceuticals Inc.
NameRoleNamed in
Ahmet K. Tutuncu, M.D., Ph.D.Executive officerDec 2011
Cam L. GarnerExecutive officerDec 2011
Jaisim K. ShahExecutive officerDec 2011
Pravin K. Soni, Ph.D.Executive officerDec 2011
William M. GerhartExecutive officerDec 2011
Brenton K. AhrensDirectorDec 2011
Cam L. GarnerDirectorDec 2011
Heath K. LukatchDirectorDec 2011
Heather K. Preston, M.D.DirectorDec 2011
Jan K. LeschlyDirectorDec 2011
William M. GerhartDirectorDec 2011